Tebao Biotech announced that the company plans to participate as a limited partner in the subscription for shares of the Tianjin Lisi Xingshen Equity Investment Partnership with 100 million yuan of its own capital. The partnership targets a total pledged capital of not less than 3 billion yuan. The investment direction is unlisted companies in the early to medium term in the field of artificial intelligence. Company director Lam Berlin plans to invest 200 million yuan to participate in the partnership. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The transaction has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for review. The relevant investment agreement has not yet been signed, and there are risks such as filing and investment returns falling short of expectations.

Tebao Biotech announced that the company plans to participate as a limited partner in the subscription for shares of the Tianjin Lisi Xingshen Equity Investment Partnership with 100 million yuan of its own capital. The partnership targets a total pledged capital of not less than 3 billion yuan. The investment direction is unlisted companies in the early to medium term in the field of artificial intelligence. Company director Lam Berlin plans to invest 200 million yuan to participate in the partnership. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The transaction has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for review. The relevant investment agreement has not yet been signed, and there are risks such as filing and investment returns falling short of expectations.